Current Report Filing (8-k)
15 June 2023 - 6:32AM
Edgar (US Regulatory)
0001684144false00016841442023-06-132023-06-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 13, 2023
____________________
Zomedica Corp. |
(Exact name of registrant as specified in its charter) |
Alberta, Canada | | 001-38298 | | N/A |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
100 Phoenix Drive, Suite 125, Ann Arbor, Michigan | | 48108 |
(Address of principal executive offices) | | (Zip Code) |
Registrant's telephone number, including area code: (734) 369-2555
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Shares, without par value | ZOM | NYSE American |
Item 5.07 Submission of Matters to a Vote of Security Holders.
An annual meeting of our shareholders was held on June 13, 2023 (the “Annual Meeting”). At the Annual Meeting, our shareholders voted on each of the following three matters:
| · | election of eight directors, each for a one-year term; |
| | |
| · | ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2023; and |
| | |
| · | an advisory vote to approve the compensation of our named executive officers as described in our management information circular and proxy statement for the Annual Meeting. |
The final vote results for each of these four matters is set forth below.
The votes cast on the election of directors were as follows:
| | For | | Withheld | | Broker Non-Vote |
Jeffrey Rowe | | 87,730,995 | | 8,616,651 | | 198,462,462 |
Robert Cohen | | 83,920,921 | | 12,426,725 | | 198,462,462 |
Chris Macleod | | 86,929,501 | | 9,418,145 | | 198,462,462 |
Pam Nichols | | 87,669,282 | | 8,678,364 | | 198,462,462 |
Johnny D. Powers | | 87,343,642 | | 9,004,004 | | 198,462,462 |
Sean Whelan | | 87,193,145 | | 9,154,501 | | 198,462,462 |
Rodney Williams | | 86,170,305 | | 10,177,341 | | 198,462,462 |
Larry Heaton | | 87,496,102 | | 8,851,544 | | 198,462,462 |
The votes cast on the ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2023 were as follows:
For: | | | 275,373,176 | |
Withheld: | | | 19,436,932 | |
Total: | | | 294,810,108 | |
The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statement for the Annual Meeting were as follows:
For: | | | 72,557,673 | |
Against: | | | 20,608,605 | |
Abstain: | | | 3,181,226 | |
Broker Non-Vote | | | 198,462,604 | |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | | Description |
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Zomedica Corp. | |
| | | | |
| By: | /s/ Peter Donato | |
| | Peter Donato | |
| | | Chief Financial Officer | |
Date: June 14, 2023 | | | |
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Jan 2024 to Jan 2025
